Together these results suggest that the increased efficacy of the BiVax/IL2Cx CD8 T cell responses to induce diabetes was not simply due to an increase of the quantity or quality of the T cell response (i.e., TCR avidity) as compared to the T cells generated in TriVax boosted mice. This evidence concerns the gene CD8A and diabetes mellitus.